[Combined modality for recurrent and disseminated ovarian cancer--CAPF combination chemotherapy and second-look...

Twenty-seven patients with advanced ovarian cancer were treated with CAPF therapy consisting of CPA, ADM, CPDD, and 5-FU. Twenty patients were evaluable for responses. Fourteen patients (70%) had a complete (6 patients) or partial response (8 patients). The median survival time for responders was 12.0+ months and 4.0 for non-responders. Leukopenia and renal toxicity were dose limiting factors. A second-look operation was performed in 12 patients who had favorable results from CAPF. A combined modality with CAPF and second-look operation seemed to be promising.